Phase

Primary endpoint

Major eligibility criteria

Chemotherapy

(intraperitoneal)

Chemotherapy

(systemic)

Status

Adjuvant

NCT00992199

II

Rate of peritoneal metastasis

T3-4NxM0

Cisplatin and 5FU

Not specified

Unknown

NCT00858338

II

Toxicity

IB-IVM0

Floxuridine

5-FU and concurrent radiotherapy

Completed

NCT00006038

II

Efficacy and toxicity

T2N1-2M0 or T3-4NanyM0

Floxuridine and leucovorin

Docetaxel, cisplatin and 5-FU

Completed

NCT00002783

II

Efficacy and toxicity

II-IVM0

Floxuridine and leucovorin

Cisplatin and 5-FU

Completed

NCT00004103

II

RR and TTF

IB-IVM0

Floxuridine and cisplatin

Cisplatin and irinotecan

Completed

NCT01683864

II/III

PC free survival

T2-4Nany and Pcyt+

MMC and cisplatin

(hyperthermic)

No

Recruiting

NCT02205008

III

RFS

Suspicious of serosal invasion

MMC and 5-FU

S-1

Recruiting

NCT01882933

III

OS

T3/4, N+ or Pcyt+

Oxaliplatin

(hyperthermic)

No

Recruiting

Palliative

NCT02024841

I

MTD and RD

Primary gastric cancer + PC or Pcyt+

Docetaxel

Cisplatin and S-1

Recruiting

NCT01525771

I/II

MTD in phase I; PFS at 6months in phase II

PC or Pcyt+

Docetaxel

Cisplatin and capecitabine

Ongoing

NCT01379482

II

OS

Primary gastric cancer + PC

Cisplatin and doxorubicin

(Hyperthermic)

FP-based

Completed

NCT01854255

II

CBR

PC

Cisplatin and doxorubicin

(pressurized aerosal)

No

Recruiting

NCT02092298

II

OS

PC or Pcyt+

MMC, cisplatin and sodium thiosulfate

No

Recruiting

NCT01739894

II

OS

PC or Pcyt+

Paclitaxel

Oxaliplatin and capecitabine

Recruiting

NCT01471132

II

OS

PC or Pcyt+

Oxaliplatin and paclitaxel

(hyperthermic)

No

Recruiting

NCT01342653

II

DFS

PC

Docetaxel and cisplatin

MMC and doxorubicin

(hyperthermic)

5-FU, docetaxel and cisplatin

Recruiting

NCT01784900

II

PFS

PC and CCR

Catumaxomab

No

Recruiting

NCT01504256

II

Rate of mCR of PC

PC

Catumaxomab

5-FU, oxaliplatin and docetaxel

Recruiting

NCT02158988

III

OS

PC

MMC and cisplatin

(hyperthermic)

Epirubicin, oxaliplatin and capecitabine +/− trastuzumab

Recruiting